Karyopharm Therapeutics reported $1.09B in Market Capitalization this June of 2026, considering the latest stock price and the number of outstanding shares.





Market Capitalization Change Date
AbbVie USD 384.69B 19.14B Mar/2026
Abbott USD 178.41B 39.46B Mar/2026
Amgen USD 189.89B 13.64B Mar/2026
AstraZeneca USD 301.25B 13.1B Mar/2026
BioCryst Pharmaceuticals USD 1.66B 64M Dec/2025
Bristol-Myers Squibb USD 123.83B 14.02B Mar/2026
Eli Lilly USD 869.02B 146.97B Mar/2026
Enanta Pharmaceuticals USD 122M 98M Dec/2024
GlaxoSmithKline GBP 83.8B 9.44B Mar/2026
Incyte USD 18.73B 660M Mar/2026
J&J USD 579.15B 78.91B Mar/2026
Karyopharm Therapeutics USD 1.05B 912M Jun/2026
Merck USD 297.1B 35.84B Mar/2026
Nektar Therapeutics USD 11.91B 11.05B Jun/2026
Novartis USD 307.76B 15.54B Mar/2026
Pfizer USD 153.81B 12.24B Mar/2026
Regeneron Pharmaceuticals USD 81.68B 560M Mar/2026
Roche Holding CHF 266.34B 55.46B Dec/2025
Takeda JPY 9.01T 1.37T Mar/2026
Tectonic Therapeutic USD 390M 96M Dec/2025
TG Therapeutics USD 5.31B 572M Mar/2026
Ultragenyx Pharmaceutical USD 2.06B 159M Mar/2026
Xencor USD 893M 200M Mar/2026